These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 1351957)
21. Levocabastine versus cromolyn sodium in the treatment of pollen-induced conjunctivitis. Ciprandi G; Cerqueti PM; Sacca S; Cilli P; Canonica GW Ann Allergy; 1990 Aug; 65(2):156-8. PubMed ID: 1974402 [TBL] [Abstract][Full Text] [Related]
22. Levocabastine eye drops: a new approach for the treatment of acute allergic conjunctivitis. Abelson MB; Weintraub D Eur J Ophthalmol; 1994; 4(2):91-101. PubMed ID: 7950341 [TBL] [Abstract][Full Text] [Related]
23. Topical levocabastine compared with orally administered terfenadine for the prophylaxis and treatment of seasonal rhinoconjunctivitis. Søhoel P; Freng BA; Kramer J; Poppe S; Rebo R; Korsrud FR; Garud O; Woxen OJ; Olsen AK J Allergy Clin Immunol; 1993 Jul; 92(1 Pt 1):73-81. PubMed ID: 8101534 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of the new ophthalmic antihistamine, 0.05% levocabastine, in the clinical allergen challenge model of allergic conjunctivitis. Abelson MB; George MA; Schaefer K; Smith LM J Allergy Clin Immunol; 1994 Sep; 94(3 Pt 1):458-64. PubMed ID: 7916020 [TBL] [Abstract][Full Text] [Related]
25. Intranasal levocabastine for the treatment of seasonal allergic rhinitis: a multicentre, double-blind, placebo-controlled trial. Dahl R; Pedersen B; Larsen B Rhinology; 1995 Sep; 33(3):121-5. PubMed ID: 8560160 [TBL] [Abstract][Full Text] [Related]
26. [Comparison of three antiallergic eyedrops in a specific conjunctival provocation test: mequitazine, levocabastine and dexamethasone]. Richard C; Bibas P; Lablache-Combier M; Allaire C J Fr Ophtalmol; 2005 Mar; 28(3):244-50. PubMed ID: 15883488 [TBL] [Abstract][Full Text] [Related]
27. Double-blind comparison of levocabastine eye drops with sodium cromoglycate and placebo in the treatment of seasonal allergic conjunctivitis. Azevedo M; Castel-Branco MG; Oliveira JF; Ramos E; Delgado L; Almeida J Clin Exp Allergy; 1991 Nov; 21(6):689-94. PubMed ID: 1685691 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Borazan M; Karalezli A; Akova YA; Akman A; Kiyici H; Erbek SS Acta Ophthalmol; 2009 Aug; 87(5):549-54. PubMed ID: 18631332 [TBL] [Abstract][Full Text] [Related]
29. Randomised double masked trial comparing the efficacy and tolerance of 0.05% mequitazine eye drops versus 0.05% levocabastine and placebo in allergic conjunctivitis induced by a conjunctival provocation test with Dermatophagoides pteronyssinus. Mortemousque B; Jacquet A; Richard C; Depont F; Colin J; Moore N Br J Ophthalmol; 2004 Mar; 88(3):336-40. PubMed ID: 14977764 [TBL] [Abstract][Full Text] [Related]
30. Topical levocabastine, a selective H1 antagonist, in seasonal allergic rhinoconjunctivitis. Bende M; Pipkorn U Allergy; 1987 Oct; 42(7):512-5. PubMed ID: 2891316 [TBL] [Abstract][Full Text] [Related]
31. A comparison of topical levocabastine and oral terfenadine in the treatment of allergic rhinoconjunctivitis. The Livostin Study Group. Allergy; 1993 Oct; 48(7):530-4. PubMed ID: 7902024 [TBL] [Abstract][Full Text] [Related]
32. New trends in the treatment of allergic conjunctivitis. Parys W; Blockhuys S; Janssens M Doc Ophthalmol; 1992; 82(4):353-60. PubMed ID: 1363981 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Secchi A; Ciprandi G; Leonardi A; Deschenes J; Abelson MB Acta Ophthalmol Scand Suppl; 2000; (230):42-7. PubMed ID: 11057350 [TBL] [Abstract][Full Text] [Related]
34. A double-blind evaluation of topical levocabastine, a new specific H1 antagonist in patients with allergic conjunctivitis. Pipkorn U; Bende M; Hedner J; Hedner T Allergy; 1985 Oct; 40(7):491-6. PubMed ID: 2866725 [TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Kidd M; McKenzie SH; Steven I; Cooper C; Lanz R; Br J Ophthalmol; 2003 Oct; 87(10):1206-11. PubMed ID: 14507747 [TBL] [Abstract][Full Text] [Related]
36. Evaluation of 0.05% levocabastine versus 4% sodium cromolyn in the allergen challenge model. Abelson MB; George MA; Smith LM Ophthalmology; 1995 Feb; 102(2):310-6. PubMed ID: 7862419 [TBL] [Abstract][Full Text] [Related]
37. Topical levocabastine is more effective than sodium cromoglycate for the prophylaxis and treatment of seasonal allergic conjunctivitis. Davies BH; Mullins J Allergy; 1993 Oct; 48(7):519-24. PubMed ID: 7902022 [TBL] [Abstract][Full Text] [Related]
38. Efficacy of levocabastine in conjunctival provocation studies. Janssens M Doc Ophthalmol; 1992; 82(4):341-51. PubMed ID: 1363980 [TBL] [Abstract][Full Text] [Related]
39. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. Ahluwalia P; Anderson DF; Wilson SJ; McGill JI; Church MK J Allergy Clin Immunol; 2001 Sep; 108(3):449-54. PubMed ID: 11544467 [TBL] [Abstract][Full Text] [Related]
40. Topical levocabastine versus sodium cromoglycate in allergic conjunctivitis. Odelram H; Björkstén B; af Klercker T; Rimås M; Kjellman NI; Blychert LO Allergy; 1989 Aug; 44(6):432-6. PubMed ID: 2572181 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]